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Abstract - Healthcare Diagnostic Industry in Indonesia is showing promising growth by the time. As one of 
the emerging countries that have the largest population in South East Asia that makes Indonesia is 
categorized as second wave emerging countries. Healthcare Diagnostic is one of the business divisions of 
Healthcare Sector PT. Siemens Indonesia. The potential, unique business behavior and niche market attracts 
management’s attention to seriously develop the business since PT. Siemens Indonesia as principal was 
handing over the business on 2011.  Division of healthcare diagnostic has officially become a division of PT. 
Siemens Indonesia – Healthcare Sector in 2011. Grow the business on a leap is the main target from handing 
over business process to Siemens Indonesia. Therefore, it required accurate business strategy to meet the 
demand and to compete with competitors so that Siemens could develop and achieve the growth on a “leap”. 
To determine the precise business strategy, the writer will require strategic analysis that includes external 
and internal. Business strategy developed should be derived down to business model and business tactic to 
give detail description of the steps taken and determine percentage numbers of “leap” growth to be achieved 
within five years from the implementation of the business strategy.  
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I. INTRODUCTION 
 
In-vitro (IVD) diagnostic is the product that 
tests blood, urine, and other human body 
fluids to give the result of one’s health 
condition. The equipment ran the test with 
the reagents, inside the reagents the blood, 
urine and other human body fluids of patient 
are tested (sample). The brand of the reagents 
must be same with the brand of the analyzing 
equipment. 
 
In-vivo (Latin for “within the living”) is the 
experimentation using a whole living 
organism as opposed to a partial or dead 
organism (Wikipedia, ca 2012). Imaging 
modalities have long been crucial to the 
researcher in observing changes either at the 
organ tissues, cells, or molecular level, in 
human responding to physiological or 
environmental changes. In-vivo  diagnostic is 
facilitating the test of human body condition 
with the participation of the body it selves by 
using the medical equipment within 
techniques. The techniques such as: Magnetic 
Resonance Imaging (MRI), Computed 
Tomography (CT), Ultrasound Sonography 
(USG), Positron Emission Tomography 
(PET), and others. 
 
Healthcare in-vitro diagnostic (IVD) will 
have a strong growth in the future. The 
forecast of growth will be 11.57% for every 
year up to 2016 (Clearstate Data, 2011). The 
potential growth of healthcare industry has 
been fully supported by Indonesian 
Government. It can be shown by increasing 
the amount of state budget on healthcare 
sector in order to facilitate more the citizens. 
More and more government hospitals are 
built in the sub-urban. Even though there is a 
subsidy from government; the procurement 
of hospital equipment is on tight competition 
in terms of quality and price. Therefore the 
big players on the healthcare equipment feel 
that the competition is going to be more 
competitive in the future. Nevertheless 
Indonesia has average annual Gross 
Domestic Product (GDP) growth from 2000 
and 2011 of 5.27% and the projection of 
growth will remain strong along the coming 
years. Combined with a population of 260 
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B. Internal Analysis 
 
In analyzing internal competitive advantage 
of Siemens Indonesia healthcare diagnostic 
division (HDX division), there are three 
foundations that will be described. There are 
resources, capabilities and core 
competencies. The analysis will give big 
picture and breakdown list of internal factors 
that Siemens Indonesia have and also to 
reflect the current internal condition. 
 
Tangible Resources Analysis 
  
Table 3. Tangible Resources of Siemens HDX 
Indonesia 
 
Intangible Resources Analysis 
  
 
Table 4. Intangible Resources of Siemens HDX 
Indonesia 
 
Capabilities Analysis 
  
 
Table 5. Capabilities of Siemens HDX Indonesia 
 
Core Competencies 
“Innovation is our lifeblood” is the strong 
motto on the Siemens Global that put the 
company core competencies is on innovation. 
Advance in technology is the main key of 
Siemens to be a big player in the market. The 
industry is also pushing the trends in how 
company providing the advance and 
sophisticated technology for users so that the 
result of patient diagnose could be more 
accurate effectively and efficiently. 
 
III. BUSINESS SOLUTION 
 
 
A. Current situation analysis as the number 
4th on the market 
Far away before Siemens acquired Dade 
Behring AG, Bayer Diagnostic AG and DPC 
Ltd (before 2007), the current local company 
that exists are representing each of the three 
companies acquired. PT. Setia Guna Medika 
was representing Bayer Diagnostic, PT. 
Behrindo Nusaperkasa was representing 
Dade Behring and PT. Karindo was 
representing DPC. The penetration and 
business strategy had been done by them self 
and it is not a common story that they 
fighting each other inside the market. 
 
In early 2009, Indonesia Government has 
effectively implementing INSW on import-
export regulation. Means the export and 
import activity on the product must be done 
by principal companies. Siemens Healthcare 
Diagnostic product must be proceed and 
imported by Siemens Indonesia. PT. Tawada 
Healthcare that has been a strong dealer for 
in-vivo products has been appointed as sole 
distributor of in-vitro diagnostic product as 
well. 
The business need to continue, therefore 
Siemens Indonesia has being appointed as 
intra companies to support parties that will 
handle ordering process in Indonesia. At 
other side, the sales and marketing activities 
remain to be done by Siemens Healthcare 
Diagnostic Hongkong. 
 
 
B. From Strategy to Models and to 
Tactics 
 
Business model refers to the logic of firm, 
the way it operates and how it creates value 
for its stakeholders. Strategy refers to the 
choice of business model through which the 
firm will compete in the market place. 
Tactics refer to the residual choices open to a 
firm by virtue of the business model that it 
employs (Casadesus R, Masanell, Ricart J.E, 
2009) 
 
In order to achieve the goals to have a leap 
growth, Siemens need to set the business 
model to shown the way it operates and 
Financial Resources • Strong capital support from 
headquarters. 
Organizational Resources • Periodic report 
• Forecast, budget and monitor the 
numbers of business along the period 
• Lean management structure 
Physical Resources • Two big plants that being separated in 
two continents (America and Europe). 
Technological Resources • 8600 invention and 53.300 patents 
granted as of 2011. 
• Complete diagnosis treatment of in-
vivo and in-vitro diagnostic. 
 
Human Resources • Total headcount = 7 people with 
different function areas. 
Innovation Resources • Siemens product will keep develop. 
Reputational Resources • The winner of customer relationship 
management on 2011 in ASEAN – 
Pacific. 
 
Functional Areas Capabilities 
Distribution Implementation of drop ship method 
Human Resources Educating, motivating and retaining 
employees 
Management Information System Using SAP R3 custom built specifically for 
Siemens 
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information and other data that could 
describe patient health condition between 
instruments.    
 
- Organize some conferences, seminars and 
events to laboratory physicians (customer 
and potential customer)  with periodically 
time containing: Education on new 
approach / method of tests 
- New product launch 
- Customer appreciation day 
 
Enhance Customer service (after-sales) 
performance and reputation During after-
sales service process, PT. Tawada Healthcare 
have taken care the process to end customers 
under the business divison of Bio Medical 
Service. End customer is using web base 
application to input service/complaint report 
and report it to PT. Tawada Healthcare. This 
application is fully controlled and monitored 
by regional office.  
 
Multi stage of process problem-solving as 
described is making slow the after sales 
services performance. Even there’s no hard 
complain from end customer due to the 
current service performance but when taking 
care the instrument with seeding program 
will demand  Siemens Indonesia to take care 
the instrument intensively as their assets. 
 
New model proposed is needed. Therefore, 
Siemens Indonesia must have engineer team 
on the level 2 (L2) to monitor and control the 
process of after-sales service. The 
communication and escalation will do on 
country level in purpose to shorten the 
process flow. 
 
All job function that had taken care by 
regional office – technical solution service is 
being reassigned to Siemens Indonesia 
engineer. Not only supporting the activity of 
L1 service, the field inspection also could be 
done by which the team and it will give the 
contribution to the performance speed and 
indirectly give impact to the reputation and 
brand awareness 
 
Price (financial flexibility) 
Base on the market survey with interview, 
Siemens equipment selling price to hospital 
is higher compare to competitors, this also 
could be indicates from analysis of product 
features and retail price on section Product 
and Price analysis.  
Siemens regional could support on discount 
for bundle purchase of instruments but it will 
not give results that Siemens will be the 
cheapest among competitors.  Other strategy 
that could be use to avoid the price war with 
competitor is by a seeding program.  
 
Seeding is marketing program that adopt the 
model from leasing method. There will be 
two models of seeding with differences of 
asset transfer ownership at the end of 
contract period. Commonly in accounting 
world it called capital lease and operation 
lease. 
 
- Capital Lease 
 
This method is offering free-instrument to the 
potential customer with variety of instrument 
needed and number of tests that generated in 
periodic. The step of implementing of this 
method shown below: 
 Making report of Historical test numbers 
that laboratory has. As shown on 
appendix B. From the historical data of 
test volume on laboratory, it is being 
converted to dollar amount and could 
show the estimation of historical 
revenue generated.    
 Making report of projection revenue. As 
shown on appendix C, the projection is 
being made with justification from its 
historical data and estimates the average 
growth for the coming years. 
 Making report of cash flow projection. 
As shown on appendix D, after knowing 
the revenue forecast that could be 
generated during the contract period. In 
this case is using 5 years contract, 
referring on common seeding contract 
program terms that applied in Siemens. 
The data could give information: the 
estimation when the investment could be 
paid-back (BEP) and shows the return 
that could be obtained each year. 
. 
The rate of return that used for calculation is 
calculated using WACC method. This 
seeding program method is way of investing. 
Therefore there will be factors need to be 
considered besides the interest rate of 
average corporate banking credit rate in 
Indonesia. 
 
- Operation Lease 
This method is an option for customers that 
have intend for acquiring Siemens IVD 
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solution. L2 engineer at country level will 
give quicker time escalation and could 
jump-in into the field for priority 
customer for indicating problem in 
equipment operations 
ii. Monitor and close the gap the service 
level to end customers and make progress 
report that could be submitted to Siemens 
management. 
 
C. Finance flexibility options for 
customers 
i. Close working with Business 
Administrator team to calculate the 
investment project forecast per laboratory 
and hospital. 
ii. Get the history data input of new 
customers and make proper projection. 
 
D. Strengthen partnership with 
distributors and sub-distributors 
i. Defining with clear the role of principal 
with distributor/sub distributor. 
ii. Monthly meeting to discuss sales-funnel. 
 
After implementation has been described 
with its activities, next part is the project 
evaluation. Siemens Indonesia-Healthcare 
Sector management, especially the head of 
HDX division must be assigned to monitor 
the implementation of each activity plan 
mentioned above.  
 
There are several things to monitor, such as: 
- Budget expenditure.  
- Activity Progress. S curve tools could be 
use to check the continuity of the project.  
- Customer feedback.  
 
V.  RECOMMENDATION  
 
Some recommendations regarding this final 
project are: 
- Business development officer need to be 
appointed. This recommendation is 
proposed due to the head of division HDX 
also covering the position of head division 
HCP. This strategy must be implemented 
continuously and fully monitor. By 
having business development officer, it 
will be a center of competence and 
backup leader in terms of project 
execution 
- Having more deep down feasibility 
studies on potential customer that will 
join seeding program as part of finance 
flexibility. The projection and calculation 
of seeding project must be done in correct 
and proper way 
- Fully commitment from country and 
regional top management must be 
obtained. This is a must in order to run the 
project smoothly by not having internal 
obstacle. 
- There will be reactions from competitor 
due to the strategy execution. Therefore 
the strategy should by dynamics to 
anticipate it and in order to keep the 
performance stay in line. 
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